Literature DB >> 10559624

BHP Disease Management. Introduction and concluding remarks.

C R Chapple1.   

Abstract

Mesh：

Year:  1999        PMID： 10559624     DOI： 10.1159/000052342

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  9 in total

Review 1.  Phytotherapeutic agents in the treatment of benign prostatic hyperplasia.

Authors:  K Dreikorn
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

2.  A prospective, randomized comparative study of monopolar transurethral resection of the prostate versus photoselective vaporization of the prostate with GreenLight 120-W laser, in prostates less than 80 cc.

Authors:  Onur Telli; Tolga Muharrem Okutucu; Evren Suer; Berk Burgu; Omer Gulpinar; Onder Yaman; Selen Bozkurt
Journal:  Ther Adv Urol       Date:  2015-02

3.  Adenovirus-mediated delivery of shRNA against bFGF mRNA suppresses growth of cultured human primary prostatic stromal cells.

Authors:  Kai Wang; Linfeng Cheng; Yinghong Liang; Donghui Liu; Kai Li; Ping Wang
Journal:  Mol Biol Rep       Date:  2010-06-06       Impact factor: 2.316

4.  The effectiveness of a treatment protocol for male lower urinary tract symptoms in general practice: a practical randomised controlled trial.

Authors:  Roelf J C Norg; Kees van de Beek; Piet J M Portegijs; C P Onno van Schayck; J André Knottnerus
Journal:  Br J Gen Pract       Date:  2006-12       Impact factor: 5.386

5.  Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia.

Authors:  Jae-Wook Chung; Seock Hwan Choi; Bum Soo Kim; Tae-Hwan Kim; Eun Sang Yoo; Chun Il Kim; Kyung Seop Lee; Tae Gyun Kwon
Journal:  Korean J Urol       Date:  2011-07-24

6.  Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia-related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity.

Authors:  Abdullah Gul; Soner Coban; Ali Riza Turkoglu; Muhammet Guzelsoy; Murat Ozturk; Nazim Abdulkadir Kankilic
Journal:  Prostate Int       Date:  2020-05-19

7.  Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey.

Authors:  M Emberton; M Marberger; J de la Rosette
Journal:  Int J Clin Pract       Date:  2007-11-19       Impact factor: 2.503

8.  Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study.

Authors:  Sung Ryul Shim; Jae Heon Kim; In Ho Chang; In Soo Shin; Sung Dong Hwang; Khae Hwan Kim; Sang Jin Yoon; Yun Seob Song
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

9.  Who are suitable for low-dose tamsulosin monotherapy as initial treatment strategy in male patients with lower urinary tract symptoms?

Authors:  Jae Heon Kim; Ji Sung Shim; Hoon Choi; Jae Young Park; Soon-Sun Kwon; Jae Hyun Bae
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.